Updates in hereditary breast cancer genetic testing and practical high risk breast management in gene carriers.

Breast cancer risk assessment and risk reduction Genetic counseling and testing Hereditary cancer Next generation multi-gene panel testing

Journal

Seminars in oncology
ISSN: 1532-8708
Titre abrégé: Semin Oncol
Pays: United States
ID NLM: 0420432

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 29 04 2020
revised: 04 05 2020
accepted: 04 05 2020
pubmed: 10 6 2020
medline: 23 1 2021
entrez: 10 6 2020
Statut: ppublish

Résumé

Testing for hereditary predisposition to breast cancer is rapidly expanding in parallel with the emerging field of molecular genetics given the associated implications for screening, risk reduction and cancer therapeutics for identified gene mutation carriers. With the advent of next generation multigene panel testing for hereditary predisposition and decreasing cost for that testing, more breast cancer patients (and unaffected family members) are undergoing cancer genetic testing. With multiple genes being tested and the myriad of possible results and implications for patients and their families, the process of genetic counseling is of paramount importance in promoting understanding by both patients and providers of risks and options for risk management. Guidelines exist to facilitate a multidisciplinary approach to management of individuals identified as being at increased risk, and there must be an appreciation for flexibility as guidelines are applied to individual families. This update summarizes recommendations regarding who may benefit from breast cancer risk assessment and genetic counseling, controversies regarding inclusion for testing and provides a framework for the practical management of high risk gene carriers.

Identifiants

pubmed: 32513422
pii: S0093-7754(20)30047-6
doi: 10.1053/j.seminoncol.2020.05.008
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

182-186

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest None.

Auteurs

Holly J Pederson (HJ)

Cleveland Clinic, Breast Center - Departments of General Surgery and Genomic Medicine Institute, Cleveland, OH. Electronic address: pedersh@ccf.org.

Ryan Noss (R)

Cleveland Clinic, Breast Center - Departments of General Surgery and Genomic Medicine Institute, Cleveland, OH.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH